EUVIMEDEUVIMED entdecken
Studienprotokoll

Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process

Abdullah Burak Uygur, Kadir Karakuş, Selime Çelik Erden, Rabia Önem, Ali Emre Öz, Ahmet Al, Umut Gölgeli, Şerifhan Mirac Sarı

Academic Journal of Neuropsychiatry and Neuropsychology · 27.06.2026 · 3 (2) · 46-49

DOI: 10.51271/ajnn-0051 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Academic Journal of Neuropsychiatry and Neuropsychology, online erschienen am 27.06.2026. Verfasst von Abdullah Burak Uygur und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The U.S. Food and Drug Administration (FDA) has increasingly focused on breakthrough molecular mechanisms, rapidly acting medications, and expanded therapeutic indications in the treatment of depression. During this period, psychiatric interventions targeting N-methyl-D-aspartate (NMDA) receptors and intracellular signaling pathways have gained prominence, moving beyond the traditional monoamine (serotonin/norepinephrine) hypothesis. This article reviews the mechanism of action, clinical adverse effects, contraindications, safe administration protocols, and treatment process associated with esketamine, one of these novel therapeutic approaches.

Zitieren

APA

Uygur, A. B., Karakuş, K., Erden, S. Ç., Önem, R., Öz, A. E., Al, A., Gölgeli, U., & Sarı, Ş. M. (2026). Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process. Academic Journal of Neuropsychiatry and Neuropsychology, 3(2), 46-49. https://doi.org/10.51271/ajnn-0051

Vancouver

Uygur AB, Karakuş K, Erden SÇ, Önem R, Öz AE, Al A, et al. Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process. Academic Journal of Neuropsychiatry and Neuropsychology. 2026;3(2):46-49. doi:10.51271/ajnn-0051

BibTeX
@article{Uygur2026,
  author = {Uygur, Abdullah Burak and Karakuş, Kadir and Erden, Selime Çelik and Önem, Rabia and Öz, Ali Emre and Al, Ahmet and Gölgeli, Umut and Sarı, Şerifhan Mirac},
  title = {Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process},
  journal = {Academic Journal of Neuropsychiatry and Neuropsychology},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {46--49},
  doi = {10.51271/ajnn-0051}
}
Kostenlos starten →